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Abstract
Background: Obesity is a risk factor for increased cardiovascular disease. Whether vitamin D deficiency modifies
this association is unclear. Here, we examined the association of obesity and vitamin D deficiency with vascular
calcification score (VCS) in incident end-stage renal disease (ESRD) patients.
Methods: A cross-sectional study was conducted with 213 ESRD patients. Vitamin D deficiency was defined as
serum 25-hydroxyvitamin D (25(OH)D) levels below 10 ng/mL, and obesity was defined as a percentage of body
fat (PBF) higher than the sex-specific median value in the cohort (>26.8% for men, >36.2% for women). VCS was
measured by plain radiographic film of the lateral abdomen in the standing position.
Results: Most ESRD patients (76.6%) had 25(OH)D deficiency at the start of dialysis. The prevalence of 25(OH)D
deficiency was much higher in obese patients than non-obese patients, and it had significant inverse association
with PBF (r = −0.315, p < 0.001). Abdominal aortic calcification was identified in 104 (48.9%) patients. VCS was
significantly higher in obese population; 2.6 (0–23) for all patients, 4.2 (0–23) for obese and 1.0 (0–12) for
non-obese patients (p < 0.001). Interestingly, vitamin D deficiency was associated with greater risk of a high
VCS, especially in obese population [odds ratio (OR) 3.02, 95% confidence interval (CI) 1.09-9.38)], but not with
non-obese patients (OR 1.82, 95% CI 0.56-5.60).
Conclusion: The magnitude and direction of the association between obesity and the risk of vascular calcification
may depend on an individual’s 25(OH)D level, a possible representative marker of cardiometabolic disturbance in
ESRD patients.
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Background
Obesity, often defined as an elevated body mass index
(BMI), has been implicated in the development and pro-
gression of adverse cardiovascular outcomes in the gen-
eral population. However, the long-term prognostic
value of obesity may be reversed in specific populations,
especially in patients with chronic illness such as coron-
ary artery disease (CAD) and chronic kidney disease
(CKD) [1]. Recent evidence has indicated that the pro-
tective effect of obesity may be conferred only to pa-
tients who have a healthy metabolic profile [2–4].
Namely, various metabolic risk factors such as insulin
resistance, decreased muscle mass, lipid disorders, and
chronic inflammation may influence the relationship be-
tween obesity and long-term outcomes in end-stage
renal disease (ESRD) patients [5]. Indeed, obese ESRD
patients who were metabolically healthy had a lower risk
of mortality than normal weight ESRD patients who
were metabolically healthy [4]. However, there was no
mortality benefit in obese but metabolically unhealthy
ESRD patients. In this context, there is an important
limitation when using BMI to diagnose obesity. Patients
with higher fat mass may have less favorable metabolic
profiles than those with higher muscle mass, even if
their BMI is same. Therefore, some authorities advocate
a definition of obesity based on sex-specific values for
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percentage of body fat (PBF) that correspond to inter-
nationally recognized BMI cut-points for defining under-
weight, overweight and obesity [6].
Apart from the well-established role of vitamin D in
CKD-mineral bone metabolism (MBD), more recent
studies have established vitamin D as a representative
parameter of cardiometabolic disturbance [7–9]. Low
serum levels of 25-hydroxyvitamin D (25(OH)D) have
been associated with higher prevalence of cardiovascular
disease, diabetes, hypertension, obesity, and dyslipidemia
[10–13]. Although the causal relationship between these
associations has been unclear, their association may
be evidentthe fact that obese population had low
vitamin D levels is well-established. In fact, obesity is
a risk factor for both vitamin D deficiency [14] and
cardiovascular disease [15, 16]. A systematic meta-
analysis showed a significant inverse association
between BMI and vitamin D deficiency status in an
adult population, and vitamin D supplementation im-
proved cardiometabolic profiles [16].
Whether vitamin D levels can modify the link between
obesity and cardiovascular risk is unclear. The purpose
of this study was to evaluate the potential role of vitamin
D for modifying the correlation between obesity, defined
as elevated percentage of body fat (PBF), and vascular
calcification score (VCS) in incident ESRD patients.
Methods
Study population and data collection
This study consisted of 269 ESRD patients who initiated
dialysis between July 2011 and June 2015. We excluded
patients who received oral vitamin D supplements in
outpatient clinics during CKD management (n = 48), had
a previous history of peritoneal dialysis or received kid-
ney transplantation (n = 5), and who had an inserted
pacemaker (n = 3), for a total of 213 patients included in
the study. This study was approved by the institutional
review board/ethics committee of Hallym University
Sacred Heart Hospital, Anyang, Korea, and all study pro-
cedures are in adherence to the Declaration of Helsinki.
Data collected included age, sex, underlying cause of
renal disease, comorbidities, systolic and diastolic blood
pressure (BP), and various laboratory parameters. Bio-
chemical analyses of hemoglobin, serum albumin, total
cholesterol, high-density lipoprotein (HDL) cholesterol,
low-density lipoprotein (LDL) cholesterol, triglycerides
(TG), calcium, phosphate, intact parathyroid hormone
(iPTH), 25(OH)D, and 1,25-dihydroxyvitamin D (1,25
(OH)2 D) levels were carried out at the start of dialysis.
Levels of 25(OH)D were determined using an electro-
chemiluminescence method (Roche Cobas 8000 System,
Tokyo, Japan). Levels ≥ 30 ng/mL were regarded as nor-
mal, while low levels between 10 – 30 ng/mL were con-
sidered to indicate vitamin D insufficiency, and very low
levels < 10 ng/mL were categorized as vitamin D defi-
ciency. In addition, more decreased 25(OH)D levels <
3 ng/mL were designated as severe vitamin D deficiency.
Also, serum high-sensitivity C-reactive protein (hs-CRP)
levels were measured using a Behring Nephelometer
(BN) II Analyzer (Dade Behring, Newark, Del., USA) by
a latex-enhanced immunoephelometric method. All
other tests were performed according to the manufac-
turer’s instructions.
Obesity evaluation and measurement of serum leptin
BMI was calculated by dividing the individual’s dry body
weight (kg) by height squared (m2). Body composition
data were obtained using a portable whole-body bioim-
pedance spectroscopy device (Body Composition Moni-
tor; Fresenius Medical Care, Bad Homburg, Germany).
The device provided objective data about fat mass, rela-
tive PBF, and fat tissue index (FTI) in which fat mass
was normalized to the body surface area (m2). Obesity
was arbitrarily defined as a PBF >26.8% for men and
>36.2% for women in our cohort (sex-specific median
value in our cohort). Also, serum leptin levels were mea-
sured using an enzyme-linked immunosorbent assay
(ELISA) kit (R&D Systems, Wiesbaden, Germany) ac-
cording to the manufacturer’s instructions.
Vascular calcification score
The VCS was determined by plain radiographic film of
the lateral abdomen in the standing position, as previ-
ously described by Verbeke et al. Briefly, abdominal aor-
tic vascular calcification was graded on a 0 to 3 scale at
each segment of the first through fourth lumbar verte-
brae based on the severity of calcification [17]. A score
of 0 denoted no aortic calcific deposits; 1 denoted small,
scattered calcific deposits less than one-third of the lon-
gitudinal wall of the aorta; 2 denoted one-third or more,
but less than two-thirds; and 3 denoted two-thirds or
more. The anterior and posterior aortas were separately
graded and the values were summed, resulting in a total
score that ranged from 0 to 24. Particularly, VCS ≥ 7 was
regarded as having severe VCS. All radiographic films
were read by two experienced radiologists without
knowledge of subjects’ clinical history.
Statistical analysis
Statistical analysis was performed using the statistical
package SPSS, version 24.0 (SPSS Inc., IL, USA). All var-
iables were expressed as the mean ± SD or median with
ranges, unless otherwise indicated. The Kolmogorov-
Smirnov test was used to analyze the normality of distri-
bution, and natural log values were used for skewed data
including hs-CRP and serum leptin levels. Pearson’s
correlation analysis was used to clarify the relationship
between measured VCS, PBF, and various parameters
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including 25(OH)D. With multiple regression analysis,
the influences of obesity and vitamin D deficiency on
VCS were assessed. Multiple logistic regression ana-
lysis was performed to evaluate the determinants of
significant vascular calcification development. A level
of p < 0.05 was considered significant.
Results
Patient characteristics
This cross-sectional study included 213 consequent
incident dialysis patients with a mean age of 63.7 ±
13.4 years; 31.9% (n = 68) were women and 64.7% (n =
138) had diabetes. Mean BMI and PBF were 23.8 ± 4.1
and 30.0 ± 10.5%, respectively. There was a definite dis-
parity between BMI and PBF in incident ESRD patients;
26.8% patients were actually obese (diagnosed by PBF
criteria) even though their BMI was less than 25 kg/m2,
whereas 9.4% were non-obese (diagnosed by PBF cri-
teria) even though their BMI was higher than 25 kg/m2
(Additional file 1: Figure S1).
Baseline characteristics of subjects with and without
obesity are shown in Table 1. Compared to non-obese
patients, obese patients were significantly older (p =
0.002), usually female in gender (p < 0.001), and diabetes
was more common (p = 0.031). In addition, significant
differences were observed in serum HDL (p = 0.035),
LDL (p = .022), TG (p = 0.001), hs-CRP (p = 0.002), and
leptin levels (p < 0.001). In addition, median serum
25(OH)D levels were significantly lower in the obese
group. Figure 1 shows the distribution of 25(OH)D levels
according to the presence of obesity. Most ESRD pa-
tients (n = 163, 76.6%) had 25(OH)D deficiency (<10 ng/
mL) at the start of dialysis, and 34.2% (n = 73) had much
lower 25(OH)D levels (<3 ng/mL, severe deficiency).
Interestingly, the prevalence of 25(OH)D deficiency was
much higher in obese patients than non-obese patients.
No subjects had normal 25(OH)D levels (≥30 ng/mL) in
the obese group (Fig. 2). In fact, serum 25(OH)D levels
had a consistent, strong negative correlation with various
representative parameters of adiposity such as PBF (r =
−0.315, p < 0.001), serum leptin (r = −0.261, p = 0.002),
and BMI (r = −0.209, p = 0.004) as well as the inflamma-
tory parameter, hs-CRP (r = −0.256, p < 0.001). Serum
25(OH)D levels also correlated weakly with serum levels
of iPTH (r = −0.16, p = 0.046). However, there was no
correlation between 25(OH)D levels and serum calcium,
phosphorus, or other metabolic parameters such as BP,
glucose, or lipid profiles.
Vascular calcification score and its relationship with
serum 25(OH)D levels
Abdominal aortic calcification was identified in 104
(48.9%) patients and 33 (15.5%) patients had severe vas-
cular calcification with VCS ≥ 7. The mean VCS was
significantly higher in the obese population; 2.6 (0–23)
for all, 4.2 (0–23) for obese, and 1.0 (0–12) for non-
obese patients (p < 0.001). When obesity is defined by
the BMI criteria, the VCS in the obese population was
3.4 (0–23), and 2.2 (0–15) for non-obese patients (p =
0.073). The prevalence of severe VCS was also higher in
obese patients than non-obese (p < 0.001 by PBF criteria,
p = 0.078 by BMI criteria). As shown in Table 2, VCS
determination revealed a strong association with age
(r = 0.370, p < 0.001), followed by serum leptin (r =
0.373, p < 0.001), hs-CRP (r = 0.339, p < 0 .001), PBF
(r = 0.331, p < 0.001), 25 (OH)D (r = −0.207, p = 0.007),
BMI (r = 0.163, p = 0.015), and serum phosphorus (r =
−0.158, p = 0.034). There was no close relationship
between VCS and iPTH or serum calcium levels in
this study.
Interestingly, in both the obese and non-obese groups,
the VCS was significantly dependent on serum 25(OH)D
levels. Figure 2 illustrates differences in VCS measured
relative to the presence of 25(OH)D deficiency. In obese,
non-obese and all patients, the VCS was higher in pa-
tients with 25(OH)D deficiency. Particularly, the differ-
ence was more clearly observed in the obese population
than the non-obese group (Fig. 2, upper). The score gap
became even larger with severe 25(OH)D deficiency
(Fig. 2, lower). Similarly, observed (O) and expected (E)
frequencies of presence or severe vascular calcification
became significantly higher with increasing severity of
low 25(OH)D levels. These findings were more marked
in the obese population (Additional file 2: Table S1).
In a multivariate logistic regression model adjusted for
age, sex, diabetes, systolic BP, previous history of CAD,
and elevated HDL cholesterol, TG, calcium and phos-
phorus levels, patients with 25(OH)D deficiency had an
increased tendency to develop vascular calcification as
well as severe vascular calcification. However, the harm-
ful effect of low vitamin D level was statistically signifi-
cant only in the obese population. In the non-obese
group, the modifying effect of 25(OH)D deficiency on
vascular calcification was unclear (Table 3). The OR for
the prevalence of severe VCS was the highest in cases of
obesity and 25(OH)D deficiency, with non-obese and
non-25(OH)D-deficient patients serving as the reference
group (OR 10.83, 95% CI, 2.85 - 18.69) (Fig. 3).
Discussion
In this cross-sectional study of 213 ESRD patients, we
found that: 1) at the start of dialysis, most patients
(76.6%) had 25(OH)D deficiency and more severely de-
creased 25(OH)D levels were also frequently observed;
2) obesity, defined as elevated PBF, was closely associ-
ated with a higher VCS and low serum 25(OH)D level;
and 3) serum 25(OH)D affected the relationship between
obesity and the risk of vascular calcification, such that
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vitamin D deficiency was associated with greater risk of
a high VCS, especially with obese population, but not
with non-obese patients. These findings suggest that the
magnitude and direction of the correlation between
obesity and the risk of vascular calcification may depend
on an individual’s 25(OH)D level, a possible representa-
tive marker of cardiometabolic disturbance. In our
knowledge, this is the first report to elucidate the
potential role of 25(OH)D deficiency for aggravating the
association between obesity and cardiovascular adverse
outcome in incident ESRD patients.
With increasing numbers of obese dialysis patients,
mortality for these patients was expected to be much
higher than that of non-obese patient. However, con-
trary to the expectation, epidemiologic studies have
shown the protective benefit of obesity in the ESRD
Table 1 Baseline characteristics
Clinical characteristics Total (n = 213) Obesity (+)a Obesity (−)
(n = 109, 51.1%) (n = 104, 48.9%) p
Age (years) 63.7 ± 13.4 66.4 ± 13.0 60.8 ± 13.3 0.002
Gender, female, n (%) 68 (31.9) 47 (43.1) 21 (20.2) <0.001
BMI (kg/m2) 23.8 ± 4.1 25.2 ± 4.3 22.2 ± 3.2 <0.001
BMI≥ 25 kg/m2, n (%) 72 (33.8) 52 (47.7) 20 (19.2) <0.001
Systolic BP (mmHg) 146.0 ± 20.8 147.3 ± 21.4 144.8 ± 20.3 0.416
Diastolic BP (mmHg) 82.1 ± 10.9 81.4 ± 11.1 83.4 ± 10.2 0.301
Coronary artery disease, n (%) 39 (18.3) 24 (22.0) 15 (14.4) 0.064
Causes of ESRD 0.044
Diabetes, n (%) 135 (63.8) 75 (68.8) 60 (57.7)
Hypertension (%) 53 (83.6) 27 (24.8) 26 (25.0)
Glomerulonephritis, n (%) 13 (6.1) 1 (0.9) 12 (11.5)
Others, n (%) 12 (5.6) 6 (5.5) 6 (5.8)
Body composition analysis
PBF (%) 30.0 ± 10.5 37.5 ± 5.4 21.3 ± 7.8 <0.001
Fat tissue index (FTI) 9.7 ± 4.4 12.7 ± 3.5 6.5 ± 2.6 <0.001
Baseline laboratory findings
Hemoglobin (g/dL) 8.9 ± 1.6 9.1 ± 1.5 8.7 ± 1.6 0.132
Serum albumin (g/dL) 3.57 ± 0.56 3.64 ± 0.54 3.49 ± 0.57 0.076
Total calcium (mg/dL) 8.1 ± 0.9 8.1 ± 0.9 8.0 ± 0.8 0.267
Corrected calcium (mg/dL) 7.9 ± 1.8 7.9 ± 1.8 7.8 ± 1.8 0.585
Phosphorus (mg/dL) 5.2 ± 0.83 5.2 ± 1.6 5.3 ± 2.0 0.400
Intact PTH 233.0 ± 171.5 236.9 ± 162.3 228.7 ± 182.0 0.743
Total cholesterol (mg/dL) 158.5 ± 42.9 162.8 ± 45.5 153.8 ± 39.7 0.152
HDL- cholesterol (mg/dL) 43.5 ± 14.4 41.3 ± 12.9 45.8 ± 15.5 0.035
LDL- cholesterol (mg/dL) 93.4 ± 33.7 99.1 ± 36.0 87.2 ± 29.9 0.022
Triglyceride (mg/dL) 124.6 ± 68.9 141.3 ± 73.2 106.6 ± 59.3 0.001
ln_hs-CRP 0.43 ± 1.24 0.68 ± 1.31 0.13 ± 1.10 0.002
25 (OH) vitamin Da 4.4 (2.2-8.0) 3.8 (2.2-6.7) 6.1 (2.6-10.1) 0.002
< 3 ng/mL 73 (34.3) 44 (40.4) 29 (27.9) <0.001
3-10 ng/mL 90 (42.3) 53 (48.6) 37 (35.6)
10-20 ng/mL 48 (22.5) 12 (11.0) 36 (34.6)
≥ 20 ng/mL 2 (0.9) 0 (0.0) 2 (1.9)
1, 25 (OH) vitamin Da 17.8 (12.1-22.7) 18.0 (12.1-25.5) 17.5 (12.8-21.6) 0.554
ln_leptin 1.86 ± 1.52 2.62 ± 1.07 0.86 ± 1.46 <0.001
adefined as a PBF(%) ≥ gender specific median value. Abbreviations: BMI body mass index, WBC white blood cell, HDL high-density lipoprotein, LDL low-density
lipoprotein, hs-CRP high-sensitivity C-reactive proteina median with IQR range
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population [1]. Although the exact reasons of this re-
verse epidemiology have been unclear as of yet, poor
nutritional status or protein-energy wasting are strong
predictors of worse outcomes in the CKD population
[18]. Recent studies have found that the benefit of
obesity could be conferred only to metabolically
healthy obese population [2, 3]. In fact, with 4,374
CKD patients, Hanks et al. reported that overweight
or obese patients who were metabolically healthy had
lower risk for mortality as compared with metabolic-
ally healthy normal weight individuals [4]. However,
there was no mortality benefit in metabolically un-
healthy obese patients compared to metabolically
healthy normal weight patients. It is very important
to point out that an individual’s metabolic profile
could be a potential and very decisive factor for
Fig. 1 The distribution of 25(OH)D levels. The prevalence of 25(OH)D deficiency was much higher in obese patients than non-obese patients
Fig. 2 The differences of VCS according to the presence of obesity and 25(OH)D levels. Vitamin D deficiency was associated with greater risk of
a high VCS especially with obese population, but not with non-obese patients (upper). The score gap became even larger when 25(OH)D levels
were very low (lower)
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determining adverse cardiovascular outcomes in pa-
tients with reduced kidney function.
In the general population, metabolic risks are often
assessed in accordance with the criteria for metabolic
syndrome. However, as more than half of ESRD patients
have diabetes, which is one important criteria of meta-
bolic syndrome, assessment of an individual’s metabolic
risks while considering only traditional metabolic com-
ponents such as BP, glucose, TG, and HDL levels has an
important limitation in the ESRD population. Recently,
vitamin D has been regarded as a possible representative
marker of cardiometabolic disturbance [7]. Various
observational studies have found a close relationship
between vitamin D deficiency and numerous adverse
extra-skeletal complications, including cardiovascular
disease, metabolic syndrome, autoimmune disorders,
neurodegenerative disorders, and cancer [8]. Moreover,
vitamin D physiology may differ between subjects with
obesity and non-obese individuals [19, 20]. A recent
meta-analysis identified a significant inverse relationship
between BMI and vitamin D status in an adult popula-
tion [19]. Correction of vitamin D deficiency improved
cardiometabolic profiles in adults with obesity [20].
However, there is limited data for evaluating the role of
vitamin D as a metabolic risk factor in ESRD patients.
Table 2 Correlations between 25(OH)D, VCS and various metabolic risk profiles
Age SBP DBP BMI PBF Leptin hsCRP 25(OH)D 1,25(OH)D P Alb HDL LDL TG
VCS 0.370** 0.058 −0.118 0.163* 0.331** 0.373** 0.339** −0.207* 0.078 −0.158* 0.083 −0.149 0.079 0.094
Age 0.124* −0.288** −0.155* 0.152* 0.152 0.166* 0.043 0.135 −0.261** 0.042 −0.096 0.068 −0.118
SBP 0.641** 0.018 −0.103 −0.079 −0.096 −0.005 0.041 0.046 −0.177* 0.189* 0.066 −0.023
DBP 0.024 −0.201* −0.098 −0.163* 0.044 0.038 0.057 −0.072 0.186* −0.072 −0.101
BMI 0.447** 0.517** 0.315** −0.209* 0.014 −0.013 0.023 −0.332** 0.045 0.202*
PBF 0.671** 0.372** −0.315** −0.047 −0.055 0.158* −0.182* 0.108 0.293**
Leptin 0.469** −0.261* −0.078 −0.043 0.237* −0.365* 0.076 0.289**
hsCRP −0.256** 0.086 −0.170* 0.112 −0.281** −0.152 0.064
25(OH)D 0.275** 0.011 0.116 0.060 −0.011 −0.147
1,25(OH)D −0.036 0.073 −0.096 0.042 0.123
P 0.003 −0.003 0.059 0.181
Alb −0.097 −0.117 −0.008
HDL 0.078 −0.330*
LDL 0.264*
*p < 0.005, **p <0.001
Table 3 The effect of 25(OH) deficiency on the presence of VCS
and severe vascular calcification: a multivariate logistic analysisa
Vascular calcification
Presence (VCS≥ 1) Severe (VCS ≥7)
OR (95% CI)a P OR (95% CI)a P
Total patients
25(OH)D deficiency
- Absence 1 - 1 -
- Presence 1.52 (0.62-3.73) 0.255 1.78 (0.77-4.55) 0.110
Obese patients
25(OH)D deficiency
- Absence 1 - 1 -
- Presence 3.02 (1.09-9.38) 0.034 5.75 (1.71-18.29) 0.005
Non-obese patients
25(OH)D deficiency
- Absence 1 - 1 -
- Presence 1.82 (0.56-5.60) 0.298 1.11 (0.07-10.95) 0.085
a adjusted with age, sex, diabetes, systolic BP, previous history of CAD, and
elevated HDL cholesterol, TG, calcium and phosphorus levels (for total
patients, PBF was further adjusted)
Fig. 3 The ORs for the prevalence of severe VCS relative to the
presence of obesity and 25(OH)D deficiency. When non-obese and
non-25(OH)D-deficient patients serve as the reference group, obese
patients with severe vitamin D deficiency had 10.83-fold increased
risk for severe VCS (95% CI 2.85-18.69)
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Moreover, whether vitamin D status could affect the link
between obesity and vascular calcification, especially in
atherosclerosis-prone ESRD population remains unclear.
First of all, our data showed significantly much higher
prevalence of 25(OH)D deficiency in our cohort com-
pared to previous data. Wolf et al. reported that 18% of
ESRD patients have 25(OH)D deficiency at the start of
dialysis [21]. However, in our data, the prevalence was
76.6%, and the difference of the prevalence of much
lower 25(OH)D levels (<3 ng/mL, severe deficiency) was
more obvious. Although various hypotheses may be pos-
sible, but racial difference may be one of the important
factors for the difference. In fact, Wolf also found sig-
nificantly lower 25(OH)D levels in black subjects com-
pared to white subjects [21]. Moreover, the prevalence of
vitamin D deficiency or insufficiency has been reported
to be significantly higher in ethnic minorities than the
white population [19, 22].
But, consistent with previous data, 25(OH)D levels
showed a strong relationship with various markers of
obesity. Particularly, PBF had the highest correlation
with 25(OH)D deficiency. Although BMI also had a
negative association with 25(OH)D, the power was much
less than PBF. Rather, adipokine levels, such as leptin,
and inflammatory parameters, such as hs-CRP, showed a
stronger relationship with 25 (OH)D levels than BMI.
Interestingly, there was no significant relationship be-
tween 25(OH)D levels and other well-known metabolic
components such as BP, HDL, TG, and glucose. Our
data suggest that serum 25(OH)D could be a potential
candidate marker for assessing metabolic risk, independ-
ent to the well-established metabolic syndrome compo-
nents. Although low vitamin D levels in obesity has been
reported in several previous data [15, 19, 23], its causes
are not fully elucidated yet. The link between increased
PBF and low vitamin D levels may involve chronic low
grade inflammation associated with adipose tissue, as
our data shows. Supporting this, recent data showed that
total body vitamin D store are significantly greater in
obese women than normal weight control, suggesting
that the enlarged adipose mass in obese individuals
serves as a reservoir for vitamin D and that the in-
creased amount of vitamin D required to saturate this
depot may predispose obese individuals to inadequate
serum 25(OH)D [24].
As expected, PBF was closely associated with VCS.
Jensky et al. reported that a 1 SD increment in abdom-
inal or visceral fat was associated with a 1.6- and 1.5–
fold increase, respectively, in risk for the presence of
thoracic aortic calcium [25]. Similarly, with non-dialysis
CKD patients, Cordeiro et al. showed that abdominal
visceral fat is associated with coronary artery calcifica-
tion scores [26]. However, the strength of our study is
that we further investigated the detailed association
according to the presence of 25(OH)D deficiency. Our
data shows that higher PBF might confer significantly
higher risk of increased VCS when 25(OH)D deficiency
is also found. Particularly, for much lower 25(OH)D
levels, higher and more severe vascular calcification was
observed. However, interestingly, the modifying role of
25(OH)D levels was only relevant with the obese popula-
tion. In the non-obese group, the effects of low vitamin
D levels were not definite. The mechanisms explaining
these observations are still unclear. But one possible ex-
planation is that the potential harmful effect of low vita-
min D may be more exaggerated in obese patients, as
obese patients usually have higher systemic inflamma-
tion and advanced atherosclerosis. In fact, several obser-
vational data showed that vitamin D supplementation
caused a significant reduction in body fat mass com-
pared with placebo [27]. Similarly, High doses of vitamin
D supplementation in diabetic patients was associated
with significant decrease in arterial properties [28].
Maybe, the anti-inflammatory effect of vitamin D is
associated with the changes of body fat mass and dis-
tribution. Also, obesity associated increased fibroblast
growth factor 23 (FGF-23) and resultant vitamin D
deficiency could potentiate the risk of vascular calcifi-
cation. In fact, FGF23 has been shown to be associ-
ated with markers of insulin resistance, dyslipidemia
and obesity, suggesting the FGF23 could be a cardio-
metabolic risk factor connecting obesity and higher
cardiovascular complications [29]. Moreover, serum
FGF23 levels are independently associated with higher
levels of inflammatory markers in patients with CKD
[30], which may play a major role in progression of
vascular calcification. In fact, Mirza et al. reported
that FGF 23 levels were higher in subjects with the
increased adiposity compared with those without, and
this potentially represent a novel pathway linking high
FGF 23 to an increased cardiovascular risk [31]. Un-
fortunately, in this study, we could not measure other
cardiometabolic risk factors except vitamin D levels.
There are some limitations in our study. First of all,
we could not consider the seasonal variations of vitamin
D levels. In general, 25(OH)D levels become lower in
winter seasons due to insufficient sun exposure [32].
However, in this study, as most patients had vitamin D
insufficiency or deficiency, the seasonal effect was
thought to be minor. Also, a large number of patients
(34.2%, n = 73) had very low 25(OH)D levels (<3 ng/mL,
defined as severe vitamin D deficiency), and such low
levels were not common in other disease populations. So
the results may not extrapolate to other groups. Second,
the causal relationship between low vitamin D and obes-
ity is not clear in this study. Although most previous
data suggest obesity causes vitamin D deficiency or in-
sufficiency, the reverse relationship is also possible.
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However, as several previous studies showed that vita-
min D supplementation could significantly reduce body
fat mass and increase serum vitamin D concentration, in
this study, we hypothesized that obesity could induce
vitamin D deficiency or insufficiency. Future studies that
evaluate the beneficial role of vitamin D supplementa-
tion in preventing development of vascular calcification
or other cardiovascular events, especially in obese pa-
tients, may be needed. Third, we only had a single meas-
urement of 25(OH)D, limiting our ability to establish the
impact of vitamin D level changes during the study
period. Last, even though we suggested the relationship
between increased body fat mass and vascular calcifica-
tion, we could not evaluate whole atherosclerotic profiles
as well as early vascular complications such as endothe-
lial dysfunction (actually, vascular calcification is a rather
later step in atherosclerosis). Similarly, the well-
established other biomarkers dealing with CKD-MBD,
such as FGF23 or serum alkaline phosphatase levels
were not measured in present study.
Conclusions
25(OH)D deficiency is very common in incident
ESRD patients. As the PBF became higher, VCS in-
creases but 25(OH)D levels decreased. Compared to
non-obese patients, obese patients had significantly
higher VCS and severe vascular calcification. Particu-
larly in the obese group, the association between PBF
and VCS was dependent on 25(OH)D levels. Vitamin
D deficiency was associated with greater risk of a
high VCS, especially in obese population, but not with
non-obese patients.
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